semaglutide gastric intestinal obstruction law office in kentucky lawyer louisiana semaglutide gi firm in louisiana semaglutide gastrointestinal kentucky semaglutide ileus law firm – semaglutide bowel obstruction law office

According to the MHRA/EMC SmPC, Wegovy commonly causes gastrointestinal side effects including nausea, vomiting, and diarrhoea, particularly during dose escalation

Crohn's Disease and Ozempic: Safety, Risks and Alternatives Ozempic (semaglutide) is a GLP-1 receptor agonist licensed in the UK for type 2 diabetes management, but its use in patients with Crohn's disease raises important safety considerations

Goal(s) Identifying your primary health goals is the best place to start

Peptides offer something different

Beat the afternoon slump Skip the sugary energy drinks and the extra coffee

It is a GLP-1 receptor agonist that helps: Control blood sugar levels (reduces HbA1c) Support weight loss (up to 8 kg in diabetic patients) Reduce hunger and appetite Protect heart and kidney health Lower risk of cardiovascular events Ozempic is approved by Indias drug regulator CDSCO in September 2025 and officially launched by Novo Nordisk in December 2025